The ability of isorhamnetin to suppress hypoxia‐induced autophagy and tumor growth in GC through PI3K/AKT/mTOR inhibition displays its potential as a therapeutic agent in hypoxic tumor environments. Here, AKT1 is linked to gastric cancer.